ReCor receives CE mark for ultrasound-based renal denervation system

Thursday, January 24, 2013 02:00 PM

ReCor Medical, a private venture-backed, early-stage company focused on ultrasound catheter technology, has received CE mark for its next-generation Paradise system, a minimally invasive 6Fr over-the-wire (OTW) ultrasound device for treating resistant high blood pressure.

The Gen 1 Paradise system previously received CE mark just over one year ago. The Gen 2 Paradise system considerably enhances efficiency while making the procedure easier and quicker. It is the only CE-marked system for renal denervation that is based on ultrasound, not radiofrequency (RF), energy. Additionally, the treatment parameters of Gen 2 have been further enhanced to reduce energy delivery to 30 seconds by maximizing cooling of the endothelium and efficiently treating the nerves circumferentially.

"The Gen 2 OTW Paradise system is designed to offer optimal non-invasive ultrasound therapy for resistant hypertension patients to reduce resistant high blood pressure," said professor Marc Sapoval, chair of the cardiovascular radiology department at Hôpital Européen Georges-Pompidou, France. "The new features of Gen 2, including an over-the-wire 6Fr device and a quicker procedure, offers patients a superior treatment option to reduce their blood pressure.”

Mano Iyer, CEO of ReCor Medical, said, "The benefit of ReCor's ultrasound approach is three-fold. Firstly, Paradise is designed to penetrate much deeper into the tissue, up to 8 millimeters; secondly, Paradise delivers heat circumferentially, to target all of the renal nerves in one location; thirdly, Paradise does this while simultaneously cooling the artery wall's surface to protect the vessel.

Iyer continued, "Our unique approach is in stark contrast to RF, which is limited in its depth of penetration to just a few millimeters, due to inconsistent arterial wall contact, as well as its inability to heat circumferentially in any given location. In addition, RF technologies generate unnecessary heating at the level of the arterial wall. Data presented at TCT 2012 concluded that renal nerves are actually much further at depth than previously thought, and run circumferentially around the renal arteries, which underscores the Paradise ultrasound advantage."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs